Among patients with type 2 diabetes, use of GLP-1 agonists may increase the risks for adhesive capsulitis and required ...

McKesson MCK delivered an 18% increase in revenues ($95.3 billion) and a 16% rise in adjusted operating profit during the ...

PepsiCo’s selloff presents the highest dividend yield in history. Find out why PEP stock might mirror the Dotcom bust ...

Response Pharmaceuticals, Inc., a clinical-stage company focused on weight management and metabolic health in high-risk populations, today announced the early completion of enrollment in a Phase 2 ...

Year-over-year revenue grows 10%, operating profit up 52%, non-GAAP operating profit up 19%Operating cash flow of $309 million Note: A webcast of ResMed's conference call will be available at 4:30 p.m ...

Q2 2025 Management View CEO Michael Farrell reported 10% global revenue growth, driven by demand across the sleep health, breathing health, and residential care software portfolios. Device sales, ...

In 2024, Lexaria made the course changing commitment to becoming an oral based drug delivery enabling technology company focused on one of the largest and fastest growing drug sectors in the world ...

UBS makes a similar comment, stating ResMed shares are trading at 23x FY26 earnings. Although this represents a 40% premium ...

Hers shares information about the average weight for women in the U.S., what women believe the ideal weight is, and the ...

Share on Pinterest Zepbound is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) drug. You inject the drug into your stomach, thigh, or upper arm.

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Oprah Winfrey says taking a GLP-1 drug such as Ozempic and Wegovy has changed her entire perspective on “thin people.” A Type 2 diabetes medication that can also aid in weight loss ...